Comparison of Fluticasone Propionate and Budesonide in Asthma Treatment
Author Information
Author(s): N. Ringdal, P. Swinburn, R. Backman, P. Plaschke, A. P. Sips, P. Kjaersgaard, G. Bratten, T. A. J. Harris
Primary Institution: Molde County Hospital, Norway
Hypothesis
Does fluticasone propionate provide better efficacy and safety compared to budesonide in treating moderate-to-severe asthma?
Conclusion
Fluticasone propionate is more effective than budesonide for treating moderate-to-severe asthma, with a better efficacy/safety ratio.
Supporting Evidence
- Fluticasone propionate showed a statistically significant improvement in morning peak expiratory flow compared to budesonide.
- Patients on fluticasone had a greater percentage of symptom-free nights than those on budesonide.
- Adverse events were similar in both treatment groups, indicating comparable safety profiles.
Takeaway
This study shows that fluticasone propionate helps asthma patients breathe better than budesonide, and it has fewer side effects.
Methodology
A 12-week, international, randomized, double-blind, parallel-group study comparing fluticasone propionate and budesonide in asthma patients.
Potential Biases
Potential bias in patient selection and reporting of outcomes.
Limitations
The study may not generalize to all asthma patients, and the follow-up duration was limited to 12 weeks.
Participant Demographics
Adults aged 18 to 75 with moderate-to-severe asthma, with a slightly higher proportion of males (53.9%).
Statistical Information
P-Value
0.003
Confidence Interval
95% CI: 16.2-25.5
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website